BDR
Group focuses on development in 4 specialized therapeutic segments, viz.
Oncology, Critical care, Gynecology & Neurology, which are its dream
segments.
Over
the years, BDR has built an undeniable reputation for its specialization in
early identification, development and introduction of new molecules, in a
continuous endeavor to make globally available high cost medicines to local
masses at affordable prices;
Innovation and development are the inalienable cornerstones of BDR group. We invest heavily in R&D activities, possess state–of-the-art API and Formulation development centers accredited by the DSIR, Government of India. Our facilities are in a state of constant & continuous upgradation, so as to keep up and meet with the constantly growing demands of the dynamic International scenario. Blending of human skill and innovative expertise of BDR often acts as a catalyst for development of desired modern technology and setting up of world class facilities.
BDR‘s
philosophy of sustained growth and consolidation is achieved by strategic
tie-ups with several globally renowned players. Today, we can boast of having
tie-ups with market leaders in almost all the strategically important emerging
markets. We are proud recipient of “Golden Award for Best Exporter” from
Pharmexcil (Export Promotion Council) consecutively since 2010.
Over
the years having credibly established ourselves as reliable API manufacturers
and suppliers, we have made forays into manufacturing and marketing of
oncological formulations, initially under contract manufacturing understanding.
Today, BDR Group has its own in-house manufacturing support for both APIs and
formulations in this critical and life saving segment.
One
such state – of - the - art manufacturing unit, specialized in Oncology oral
formulations, is already commissioned and is into production. This unit located
in Vadodara, Gujarat State is both WHO GMP and EU-GMP compliant. More audits at
the hands of similar international Agencies as a prelude to such recognition
are in the anvil starting with ANVISA, Brazil, in the near future.
On a
parallel note, BDR now has ambitious plans to manufacture specialized
Oncological Injectable dosage forms as the next giant step. Towards the initial
step, the manufacturing site in Halol District in Gujarat has been acquired and
construction work is all set to commence. Once ready and operational, this
facility will target for approval from various international accreditation
agencies, including from US, Europe, African and Asian Health Authorities.
An API
facility dedicated to Biotech products and another formulation plant at Savli,
Vadodara, under SEZ promoted by the Gujarat government will fulfill BDR’s
ambitious long term goals being self – reliant in manufacturing.
For more updates follow www.globalpharmanews.co.in
Thank you for visiting my website, Visit again for latest pharma
updates
No comments:
Post a Comment